

sis of spectral analysis (UV, IR, ^1H NMR, ^{13}C NMR, DEPT, ^1H - ^1H COSY, ^1H - ^{13}C COSY), they were identified as 4-propenyl-phenyl-2-methyl butanoate (I) and 4-methoxy-1-propenyl-phenyl-2-methyl butanoate (II). I is a new compound named thellungianin F. II was obtained from this plant for the first time.

Key Words *Pimpinella thellungiana* thellungianin F

A New Indole Derivative Isolated from the Root of Tuber Fleeceflower (*Polygonum multiflorum*)

Yang Xiuwei* Gu Zheming** Ma Chaomei** Masao Hattori*** Tsuneo Namba***

National Research Laboratory of Natural and Biomimetic Drugs, Beijing Medical University (100083)

Abstract From the root of *Polygonum multiflorum* Thunb., a new indole derivative, named Indole-3(L- α -amino- α -hydroxy propionic acid)methyl ester (XI), was isolated together with the ten known compounds, chrysophanol (I), physcione (II), emodin (III), citreorosein (IV), chrysophanol 8-O- β -D-glucopyranoside (V), physcione 8-O- β -D-glucopyranoside (VI), emodin 8-O- β -D-glucopyranoside (VII), torachrysone 8-O- β -D-glucopyranoside (VIII), 2,3,5,4'-tetrahydroxystilbene-2-O- β -D-glucopyranoside (IX), and methylgallate (X). Their structures were determined by spectroscopic means. These anthraquinone compounds and aloe-emodin (XII), rhein (XIII), aloe-emodin 8-O- β -D-glucopyranoside (XIV), chrysophanol 8-O- β -D-(6'-O-malonyl)glucopyranoside (XV), sennoside A (XVI) and sennoside B (XVII) had no inhibitory effect against recombinant HIV-1 protease at concentration of 100 $\mu\text{mol/L}$ in vitro.

Key Words Root of *Polygonum multiflorum* Indole derivative Indole-3(L- α -amino- α -hydroxy propionic acid)methyl ester Recombinant HIV-1 protease

1 Introduction

The root of *Polygonum multiflorum* Thunb. (*Polygonaceae*), He shou wu, is a tonic drug, invigorate the liver and kidney, tonifying the kidney, and for treatment of yin-deficiency of liver and kidney, vertigo, insomnia, lassitude of the loins and legs in Chinese medicine^[1]. Our pharmacological results showed that five-day successive *po* administration of an EtOH extract of root of *P. multiflorum* can inhibit significantly the activity of monoamine oxidase B (MAO-B), though the extract showed no activity for MAO-A in male senescence-accelerated mice^[2].

As a part of our chemical investigations on the active constituents from natural

sources, we report chemical investigation of the root of *P. multiflorum* which led to the isolation of eleven compounds from the EtOAc and n-BuOH soluble fractions of the ethanolic extract, and inhibitory effects of some anthraquinone compounds against recombinant (REC) HIV-1 protease in vitro.

2 Results and Discussion

An ethanolic extract of the root of *P. multiflorum* was fractionated into EtOAc- and n-BuOH-soluble fractions. Repeated column chromatography of these fractions led to the isolation of eleven compounds. One new indole derivative was isolated and identified as Indole-3(L- α -amino- α -hydroxy propionic acid)methyl ester (XI). Ten known

* 北京医科大学天然药物及仿生药物国家重点实验室(北京, 100083)

** Chengdu College of Traditional Chinese Medicine, Chengdu 610075, China

*** Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-01, Japan

compounds, chrysophanol (I), physcione (II), emodin (III), citreorosein (IV), chrysophanol 8-O- β -D-glucopyranoside (V), physcione 8-O- β -D-glucopyranoside (VI), emodin 8-O- β -D-glucopyranoside (VII), torachrysone 8-O- β -D-glucopyranoside (VIII), 2,3,5,4'-tetrahydroxystilbene 2-O- β -D-glucopyranoside (IX), and methylgallate (X) were also isolated and fully characterized. Their ^{13}C NMR data were shown in Table 1, respectively.

Compound XI showed IR bands at 3458, 1626, 1104, and 750 cm^{-1} for N-H, ester, C-O, and Ar-H, respectively. Its EI-MS spectrum showed the quasi molecular ion peak at m/z 234, corresponding to $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_3$. The elucidated formula was further confirmed by HR-MS and elementary analysis. Its ^1H and ^{13}C NMR spectra (Table 2) were quite similar to those of L-tryptophan, except for some signals in the C_3 (to shift downfield by 1.7 ppm) and side-chain. Therefore, compound XI should be a 3-substituted indolyl skeleton. The ^{13}C NMR data, as well as the DEPT spectra, indicated the presence of 4 carbons of which were O-methyl, carbonyl ester (δ 171.4), quaternary, and methylene in side-chain, respectively. ^1H and ^{13}C NMR and HMQC spectra were also consistent with the proposed structure (Fig. 1). Compound XI was found to be optically active, $[\alpha]_{\text{D}} - 48^\circ$ (c, 1, MeOH). The above-mentioned spectral findings support the structure for compound XI as Indile-3-(L- α -amino- α -hydroxy propionic acid) methyl ester. This compound was isolated for the first time from the natural source.

In addition, we screened thirteen anthraquinones and one naphthalene for anti-

HIV-1 protease activity. All compounds showed no inhibitory effect at concentrations of $100\text{ }\mu\text{mol/L}$ *in vitro* (Table 3).




Fig 1 Structure of Compound XI

3 Experimental

3.1 Apparatus: Melting points were determined on a Yanagi motomicro-melting point apparatus and are uncorrected. IR spectra were taken on a Hitachi 260-10 and Perkin-Elmer 983 infrared spectrometer. UV were measured with a Shimadzu UV-2200 spectrophotometer (Shimadzu, Kyoto). ^1H NMR and ^{13}C NMR were measured with JEOL GX-270 (^1H , 270 MHz, ^{13}C , 67.5 MHz), Varian Gemini 300 (^1H , 300 MHz, ^{13}C , 75.5 MHz) and 400 (^1H , 400 MHz, ^{13}C , 100 MHz). Tetramethylsilane was used as an internal standard. Optical rotations were measured with JASCO DIP-4 automatic polarimeter. EI-MS, FAB-MS and HR-MS were measured with JEOL JMS-DX 300 L mass spectrometer.

3.2 Chromatography: Wako gel 100 (Wako Pure Chemical Industries Co., Osaka, Japan) was used for column chromatography. Thin-layer chromatography (TLC) plates (Merck Kieselgel 60 F₂₅₄; layer thickness, 0.25 mm) were purchased from E. Merck (Darmstadt, FRG).

3.3 Materials and Reagents: Roots of *P. multiflorum* were collected at Ma-er-kang county, Sichuan province of China, in August 1991. The plant was identified by professor Zhe Ming gu. Aloe-emodin (XII), rhein (XIII), aloe-emodin 8-O- β -D-glucopy-

ranoside (XIV), chrysophanol 8-O- β -D-(6'-O-malonyl) glucopyranoside (XV), sennoside A (XVI), and sennoside B (XVII) were isolated from the rhizomes of *Rheum qinlingense* and *R. palmatum*.

The recombinant (Rec) HIV-1 protease was obtained as reported^[3]. L-Tryptophan was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan).

3.4 Extraction and fractionation: Dried and pulverised roots (2.5 kg) were refluxed with ethanol (4 L) five times for one hour each time. The ethanol layer was filtered and concentrated in vacuo to yield ethanol extract (285 g, PME, yields. 11.4%). The PME was suspended in H₂O (1 L), and extracted successively with ethyl acetate (2 L $\times$ 5) and n-butanol (2 L $\times$ 5) to yield EtOAc extract (41 g, 1.64%), n-BuOH extract (185 g, 7.4%), and water extract (49 g, 19.6%), respectively.

The EtOAc extract (40 g) was subjected to column chromatography on silica gel and eluted with cyclohexane-CHCl₃ (1 : 1), CHCl₃, and CHCl₃-MeOH gradually increasing polarity. The elutes were collected in 100 mL portions, monitored by TLC. Fraction 5 eluted with CHCl₃ were subjected to repeated CC to yield compounds I (33 mg), II (32 mg), III (25 mg), and IV (18 mg). Similarly, fractions eluted with CHCl₃-MeOH gave compounds V (250 mg), VI (320 mg), VII (28 mg), and VIII (15 g).

The n-BuOH extract (100 g) was subjected to column chromatography on silica gel and eluted with CHCl₃ and CHCl₃-MeOH gradually increasing polarity. The elutes were collected in 100 mL portions, monitored by TLC. Fractions eluted with CHCl₃ gave compound IX (30 mg). Fractions eluted

with CHCl₃-MeOH (4 : 1) gave compound V (48 mg), VI (50 mg), VII (10 mg), VIII (1 g), IX (51 mg), X (62 mg). Fractions eluted with CHCl₃-MeOH (3 : 2) gave compound XI (102 mg).

Compound I (chrysophanol): monoclinic (benzene), mp 196 °C ~ 197 °C; IR_{max} (KBr) cm⁻¹: 3429 (OH), 1677 (free C=O), 1626 (chelated C=O), 1560, 1457; UV λ_{max} nm (log ϵ) EtOH: 225 (4.2), 256 (2.4), 277 (1.2), 287 (1.6); EI-MS m/z: 254 [M⁺]; ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 11.80 (2 H, s, C_{1,8}-OH), 7.66 (1 H, d, J=8.0 Hz, C₅-H), 7.56 (1 H, dd, J=1.2, 8.0 Hz, C₆-H), 7.39 (1 H, s, C₄-H), 7.26 (1 H, d, J=8.0 Hz, C₇-H), 7.07 (1 H, s, C₂-H), 2.33 (3 H, s, Me) 3.94 (3 H, s, Me). ¹³C NMR: see Table 1.

Compound II (physcione): monoclinic needles (benzene), mp 207 °C ~ 208 °C; IR_{max} (KBr) cm⁻¹: 3429 (OH), 1684 (free C=O), 1626 (chelated C=O), 1557, 1541, 1506; UV λ_{max} nm (log ϵ) EtOH: 223 (4.2), 253 (1.8), 285 (2.2); EI-MS m/z: 284 [M⁺]; ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 12.03 (1 H, s, C₈-OH or C₁-OH), 11.95 (1 H, s, C₁-OH or C₈-OH), 7.54 (1 H, d, J=1.2 Hz, C₄-H), 7.20 (1 H, d, J=1.2 Hz, C₅-H), 7.19 (1 H, d, J=2.4 Hz, C₂-H), 6.88 (1 H, d, J=2.4 Hz, C₇-H), 3.94 (3 H, s, OMe), 2.43 (3 H, s, Me). ¹³C NMR: see Table 1.

Compound III (emodin): orange needles (EtOH), mp 255 °C ~ 257 °C; IR_{max} (KBr) cm⁻¹: 3429 (OH), 1684 (free C=O), 1632 (chelated C=O), 1558, 1541, 1485; UV λ_{max} nm (log ϵ) EtOH: 221 (4.4), 253 (1.9), 266 (2.1), 290 (2.5); EI-MS m/z: 270 [M⁺]; ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 12.03 (1 H, s, C₈-OH or C₁-OH), 11.95 (1

H, s, C₁-OH or C₈-OH), 11.33(1 H, s, C₆-OH), 7.41(1 H, d, J=1.2 Hz, C₄-H), 7.08(1 H, d, J=1.2 Hz, C₂-H), 7.06(1 H, d, J=2.4 Hz, C₅-H), 6.54(1 H, d, J=2.4 Hz, C₇-H), 2.38(3 H, s, Me). ¹³C NMR; see Table 1.

Compound IV (citreorosein): orange needles (MeOH), mp 277 °C ~ 279 °C; IR_{max} (KBr) cm⁻¹: 3442 (OH), 1673 (free C=O), 1627 (chelated C=O), 1561, 1432; EIMS m/z: 286 [M⁺]; ¹H NMR (270 MHz, DMSO-d₆) δppm: 12.09(1 H, s, C₈-OH or C₁-OH), 12.06(1 H, s, C₁-OH or C₈-OH), 7.63(1 H, s, C₅-H), 7.24(1 H, s, C₇-H), 7.12(1 H, d, J=2.1 Hz, C₄-H), 6.59(1 H, d, J=2.1 Hz, C₂-H), 4.60(2 H, brs, C₃-CH₂OH). ¹³C NMR; see Table 1.

Compound V (chrysophanol 8-O-β-D-glucopyranoside): yellow powder; IR_{max} (KBr) cm⁻¹: 3387 (OH), 1672 (free C=O), 1632 (chelated C=O), 1594, 1445, 1076 (sugar C-O); UVλ_{max} nm (log ε) EtOH: 221 (4.4), 258 (3.0), 283 (2.2); EI-MS; m/z 416 [M⁺], 254 [M⁺ - glc]; FAB-MS; m/z 416 [M⁺]; ¹H NMR (300 MHz, DMSO-d₆) δppm: 12.85(1 H, s, C₁-OH), 7.88(1 H, dd, J=1.5, 6.3 Hz, C₅-H), 7.85(1 H, dd, J=7.7, 8.0 Hz, C₆-H), 7.71(1 H, dd, J=1.5, 7.9 Hz, C₇-H), 7.51(1 H, d, J=1.2 Hz, C₄-H), 7.20(1 H, d, J=1.2 Hz, C₂-H), 5.17(1 H, d, J=7.8 Hz, anomeric H), 3.71(1 H, dd, J=5.6, 10.3 Hz, G-C₆-Ha), 3.50(1 H, dd, J=5.9, 11.9 Hz, G-C₆-Hb), 3.46(1 H, dd, J=3.2, 8.5 Hz, G-C₂-H), 3.43(1 H, dd, J=3.4, 8.1 Hz, G-C₅-H), 3.31(1 H, dd, J=5.3, 9.0 Hz, G-C₃-H), 3.24(1 H, dd, J=5.1, 9.2 Hz, G-C₄-H). ¹³C NMR; see Table 1.

Compound VI (physcione 8-O-β-D-glucopyranoside): yellow needles (Me

OH), mp 244 °C ~ 245 °C; IR_{max} (KBr) cm⁻¹: 3400 (OH), 1670 (free C=O), 1630 (chelated C=O), 1595, 1076 (sugar C-O); UVλ_{max} nm (log ε) MeOH: 221 (4.3), 245 (3.4), 269 (2.2), 277 (1.3); FAB-MS; m/z 446 [M⁺]; ¹H NMR (300 MHz, DMSO-d₆) δppm: 12.81(1 H, s, C₁-OH), 7.59(1 H, d, J=1.2 Hz, C₄-H), 7.43(1 H, d, J=1.2 Hz, C₅-H), 7.25(1 H, d, J=1.2 Hz, C₂-H), 7.04(1 H, d, J=1.2 Hz, C₇-H), 5.51(1 H, d, J=7.8 Hz, anomeric H), 3.96(3 H, s, OMe), 3.71(1 H, dd, J=5.6, 10.3 Hz, G-C₆-Ha), 3.50(1 H, dd, J=5.9, 11.9 Hz, G-C₆-Hb), 3.46(1 H, dd, J=3.2, 8.5 Hz, G-C₂-H), 3.43(1 H, dd, J=3.4, 8.1 Hz, G-C₅-H), 3.31(1 H, dd, J=5.3, 9.0 Hz, G-C₃-H), 3.24(1 H, dd, J=5.13, 9.2 Hz, G-C₄-H), 2.43(3 H, s, Me). ¹³C NMR; see Table 1.

Compound VII (emodin 8-O-β-D-glucopyranoside): yellow powder; IR_{max} (KBr) cm⁻¹: 3409 (OH), 1732 (free C=O), 1628 (chelated C=O), 1596, 1508, 1477, 1073 (sugar C-O); UVλ_{max} nm (log ε) EtOH: 221 (4.1), 258 (2.2), FAB-MS; m/z 432 [M⁺]; ¹H NMR (300 MHz, DMSO-d₆) δppm: 13.17(1 H, s, C₁-OH), 11.26(1 H, s, C₆-H), 7.46(1 H, d, J=1.2 Hz, C₄-H), 7.29(1 H, d, J=1.2 Hz, C₅-H), 7.15(1 H, d, J=1.2 Hz, C₂-H), 6.70(1 H, d, J=1.2 Hz, C₇-H), 5.07(1 H, d, J=7.2 Hz, anomeric H), 3.71(1 H, dd, J=5.6, 10.3 Hz, G-C₆-Ha), 3.50(1 H, dd, J=5.9, 11.9 Hz, G-C₆-Hb), 3.46(1 H, dd, J=3.2, 8.5 Hz, G-C₂-H), 3.43(1 H, dd, J=3.4, 8.1 Hz, G-C₅-H), 3.31(1 H, dd, J=5.3, 9.0 Hz, G-C₃-H), 3.24(1 H, dd, J=5.13, 9.2 Hz, G-C₄-H), 2.40(3 H, s, Me). ¹³C NMR; see Table 1.

Compound VIII (torachrysone 8-O-β-D-

glucopyranoside): yellow needles, (MeOH), mp 151 °C ~ 153 °C; IR_{max} (KBr) cm⁻¹: 3387 (OH), 1620 (free C=O), 1585; UVλ_{max} nm (log ε) MeOH: 235 (4.55), 240 (4.66), 260 (4.55), 271 (4.22), 312 (3.32), 325 (3.81), 340 (4.1); FAB-MS (positive) m/z: 409 [M⁺]; ¹HNMR (270 MHz, CD₃OD) δppm: 7.03 (1 H, s, C₄-H), 7.01 (1 H, d, J=2.2 Hz, C₅-H), 6.82 (1 H, d, J=2.2 Hz, C₇-H), 5.09 (1 H, d, J=7.3 Hz, G-C₁-H), 3.95 (1 H, d, J=2.0, 12.2 Hz, G-C₆-Ha), 3.86 (3 H, s, OMe), 3.75 (1 H, dd, J=5.1, 12.1 Hz, G-C₆-Hb), 3.40 ~ 3.70 (4 H, m, G-C_{2,5}-H), 2.58 (3 H, s, COMe), 2.29 (3 H, s, C₃-Me); ¹³CNMR (67.5 MHz, CD₃OD) δppm: 208.9 s(CO), 161.2 s(C₈), 157.9 s(C₆), 154.5 s(C₁), 139.9 s(C₃), 136.2 s(C₂), 124.8 s(C_{8a}), 121.1 d(C₄), 111.1 s(C_{4a}), 105.2 d(C₅ or C₇), 105.1 d(C₇ or C₅), 103.3 d(G-C₁), 79.6 d(G-C₃), 78.9 d(G-C₅), 75.7 d(G-C₂), 72.1 d(G-C₄), 63.2 t(G-C₆), 56.8 q(OMe), 33.4 q(COMe), 21.0 q(C₃-Me).

Compound IX (2,3,5,4'-tetrahydroxys-tilbene-2-O-β-D-glucopyranoside): yellowish needles (EtOH), mp 184 °C ~ 186 °C; IR_{max} (KBr) cm⁻¹: 3275 (OH), 1604 (free C=O), 1601 (sugar C-O); UVλ_{max} nm (log ε) MeOH: 216 (4.22), 308 (4.40), 319 (4.32); FAB-MS (positive) m/z: 407 [M⁺ + 1]; ¹HNMR (400 MHz, CD₃OD) δppm: 7.70 (1 H, d, J=16.5 Hz, β-H), 7.44 (2 H, d, J=8.6 Hz, C_{2',6'}-H), 6.92 (1 H, d, J=16.5 Hz, α-H), 6.76 (2 H, d, J=8.6 Hz, C_{3',5'}-H), 6.62 (1 H, d, J=2.7 Hz, C₆-H), 6.25 (1 H, d, J=2.7 Hz, C₄-H), 4.51 (1 H, d, J=7.6 Hz, G-C₁-H), 3.82 (1 H, dd, J=2.4, 12.0 Hz, G-C₆-Ha), 3.76 (1 H, dd, J=4.0, 12.0 Hz, G-C₆-Hb), 3.52 ~ 3.60 (2 H, m, G-C_{3,4}-H), 3.41 ~ 3.46 (1 H, m, G-C₂-H),

3.25 ~ 3.29 (1 H, m, G-C₅-H); ¹³CNMR (100 MHz, CD₃OD) δppm: 159.1 s(C_{4'}), 156.7 s(C₅), 152.8 s(C₃), 138.7 s(C₂), 134.5 s(C₁), 131.7 s(C_{1'}), 130.9 d(C₆), 130.0 d(C_{3',5'}), 122.6 d(C_a), 117.2 d(C_{2',6'}), 109.0 d(C₆), 104.4 d(C₄), 103.6 d(G-C₁), 79.0 d(G-C₃), 78.7 d(G-C₅), 76.3 d(G-C₂), 71.6 d(G-C₄), 63.0 t(G-C₆).

Compound X (methylgallate): colorless needles (EtOH-MeOH), mp 197 °C ~ 199 °C; IR_{max} (KBr) cm⁻¹: 3382 (OH), 1696, 1622, 1532; UVλ_{max} nm (log ε) MeOH: 221 (4.5), 278 (4.0); EI-MS m/z: 184 [M⁺]; ¹HNMR (300 MHz, DMSO-d₆) δppm: 3.78 (3 H, s, OMe), 7.00 (2 H, s, C_{2,6}-H); ¹³CNMR (75 MHz, DMSO-d₆) δppm: 166.3 s(-COOH), 145.5 s(C_{3,5}), 138.3 s(C₄), 119.4 s(C₁), 108.5 d(C_{2,6}), 51.5 q(OMe).

Compound XI [Indole-3 (L-α-amino-α-hydroxy-propionic acid) methyl ester]: yellowish powder; [α]_D -48° (c, 1, MeOH); IR (KBr) cm⁻¹: 3458 (N-H), 1626 (ester C=O), 1104 (C-O), 750 (Ar-H); EI-MS m/z: 234 [M⁺], 219 [M⁺ - O + H], 201 [M⁺ - O + H - H₂O], 187 [201 - N], 142 [M⁺ - C₂H₆O₃N], 130 [M⁺ - C₃H₆O₃N], 116 [M⁺ - C₄H₈O₃N]. Anal. (%) Calcd. for C₁₂H₁₄O₃N₂: C 61.52, H 6.02, O 20.49, N 11.96; Found: C 61.94, H 6.04, O 20.31, N 11.81; HR-MS: Calcd for C₁₂H₁₄O₃N₂ [M⁺]: 234.1880, Found: 234.1886; ¹HNMR (270 MHz, CD₃OD) δppm: 7.63 (1 H, d, J=7.8 Hz, C₁₁-H), 7.35 (1 H, d, J=8.1 Hz, C₈-H), 7.19 (1 H, s, C₂-H), 7.11 (1 H, dd, J=7.0 Hz, C₉-H), 7.03 (1 H, dd, J=7.0, 7.0 Hz, C₁₀-H), 3.37 (2 H, s, -CH₂-), 3.26 (3 H, s, COMe); ¹³CNMR; see Table 2.

3.5 Rec HIV-protease Assay: Thirty four μL of 50 μmol/L acetate buffer (pH 5.0) containing 2 μg of a substrate (His-Lys-Ala-

Arg-Val-Leu-(pNO₂-Phe)-Glu-Ala-Nle-Ser-NH₂) was mixed with 4.0 μL of a compound solution(using H₂O-DMSO=1 : 1 as solvent), THEN 2 μL of recHIV-1 protease (1/100) was added into this mixture. The reaction mixture was incubated at 37 °C for one and a half hour and then terminated by heating at 90 °C for one min. The hydrolysate (pNO₂-Phe-Glu-Ala-Nle-Ser-NH₂) and remained substrate were quantitatively analyzed by reversed-phase HPLC (LiChrospher 100 RP-18 column(250 mm×4 mm, Merck,Darmstadt,Germany)with a gradient

of acetonitrile(18%~34%)in 0.1% trifluoroacetic acid (TFA) at a flow rate of 1.0 mL/min. The elution profile was monitored at 280 nm. The substrate and the hydrolysate were eluted at 9.6 and 3.9 min, respectively. The peak areas were calculated with an integrator C-R1A Chromatopac (Shimadzu). The inhibitory activity of a compound on HIV-protease was calculated as follows: Inhibition(%) = (A_{control} - A_{sample}) × 100/A_{control} (where A is a relative peak area of the hydrolysate). Acetylpepstatin was used as a positive control.

Table 1 ¹³CNMR spectral data of compounds I ~ VII

No.	I	II	III	IV	V	VI	VII
1a	116.3 s	113.1 s	113.1 s	114.0 s	114.9 s	114.4 s	114.4 s
1	161.5 s	161.3 s	161.3 s	161.4 s	161.8 s	160.7 s	161.0 s
2	119.5 d	119.5 d	120.3 d	117.0 d	119.5 d	124.2 d	124.1 d
3	149.3 s	149.2 s	148.0 s	152.7 s	147.8 s	147.1 s	146.8 s
4	124.6 d	120.8 d	123.8 d	120.7 d	122.7 d	119.4 d	119.2 d
4a	133.5 s	132.5 s	132.5 s	132.8 s	132.1 s	132.0 s	132.0 s
5a	133.2 s	134.8 s	134.8 s	135.1 s	134.9 s	136.3 s	136.4 s
5	120.7 d	108.7 d	108.7 d	108.8 d	124.2 d	107.4 d	108.4 d
6	137.5 d	165.5 s	165.5 s	165.5 s	136.1 d	164.7 s	164.1 s
7	124.0 d	107.8 d	107.8 d	107.8 d	121.5 d	106.5 d	108.4 d
8	161.7 s	162.1 s	164.3 s	164.4 s	158.4 s	161.7 s	161.7 s
8a	113.5 s	113.7 s	108.7 s	108.8 s	118.5 s	113.4 s	113.4 s
9	191.8 s	189.4 s	189.4 s	189.6 s	187.9 s	186.4 s	186.4 s
10	181.7 s	180.9 s	180.9 s	181.2 s	182.3 s	182.0 s	182.0 s
3-Me	21.8 q		21.4 q		21.7 q	21.4 q	21.4 q
CH ₂ OH				62.0 t			
OMe		55.6 q				56.1 q	
G-1					100.7 d	100.7 d	100.9 d
G-2					73.5 d	73.3 d	73.3 d
G-3					76.7 d	76.6 d	76.3 d
G-4					69.7 d	69.8 d	69.5 d
G-5					77.5 d	77.5 d	77.3 d
G-6					60.8 t	60.8 t	60.6 t

Table 2 ¹³C NMR spectral data of L-Tryptophan and compound XI

C 位	Tryptophan	Compound XI
2	126.1 d	125.9 d
3	108.8 s	110.5 s
4a	137.8 s	138.5 s
4	123.4 d	123.4 d
5	119.6 d	120.3 d
6	120.8 d	120.8 d
7	113.3 d	113.3 d
7a	127.8 s	129.3 s
1'	175.5 s	171.4 s
2'	56.4 d	81.3 s
3'	27.6 t	25.4 t
OMe		53.6 q

Table 3 Inhibitory Effect of Compounds of Anthraquinones and Naphthalene to Recombinant HIV-1 Protease

Compounds	Inhibition(%)	Compounds	Inhibition(%)
I	2.8	VII	2.1
II	5.3	XII	1.5
III	5.1	XIII	6.7
IV	3.0	XIV	4.0
V	1.4	XV	1.0
VI	1.9	XVI	0
VII	3.4	XVII	2.8

Reference

- 1 Dictionary of Chinese Materia Medica. Publishing House of Science and Technology of Shanghai, Shanghai, 1975. 1135
- 2 Yang XW. China Journal of Chinese Materia Medica, 1996, 21(1):48
- 3 Kusumoto IT *et al.* Shoyakugaku Zasshi, 1992, 46:190

摘要 从何首乌(*Polygonum multiflorum* Thunb.)的根中分离出 11 个化合物,根据光谱学分析分别鉴定为:大黄酚(chrysophanol, I)、大黄素甲醚(physcione, II)、大黄素(emodin, III)、 ω -羟基大黄素(citreorosein, IV)、大黄酚 8-O- β -D-吡喃葡萄糖苷(chrysophanol 8-O- β -D-glucopyranoside, V)、大黄素甲醚 8-O- β -D-吡喃葡萄糖苷(physcione 8-O- β -D-glucopyranoside, VI)、大黄素 8-O- β -D-吡喃葡萄糖苷(emodin 8-O- β -D-glucopyranoside, VII)、决明酮 8-O- β -D-吡喃葡萄糖苷(torachrysone 8-O- β -D-glucopyranoside, VIII)、2,3,5,4'-四羟基芪 2-O- β -D-吡喃葡萄糖苷(2,3,5,4'-tetrahydroxystilbene 2-O- β -D-glucopyranoside, IX)、没食子酸甲基酯(methylgallate, X)和吲哚-3-(L- α -氨基- α -羟基丙酸)甲酯[Indole-3-(L- α -amino- α -hydroxy propionic acid)methyl ester]。其中,化合物 XI 为新的天然产物。上述蒽醌和萘类化合物以及芦荟大黄素(aloe-emodin, XII)、大黄酸(rhein, XIII)、芦荟大黄素 8-O- β -D-吡喃葡萄糖苷(aloe-emodin 8-O- β -D-glucopyranoside, XIV)、大黄酚 8-O- β -D-(6'-O-丙酰基)吡喃葡萄糖苷(chrysophanol 8-O- β -D-(6'-O-malonyl)glucopyranoside, XV)、番泻叶苷 A(sennoside A, XVI)、和番泻叶苷 B(sennoside B, XVII)在 100 μ mol/L 离体条件下,对重组 HIV-1(Recombinant HIV-1)蛋白酶活性无抑制作用。

关键词 何首乌 吲哚衍生物 吲哚-3-(L- α -氨基- α -羟基丙酸)甲酯 重组 HIV-I 蛋白酶 (1997-05-12 收稿)

黑参中的酚甙

兰州医学院药理学系(730000) 李 冲* 张承忠 刘 美**

摘要 从黑参中提取分离出 3 种酚甙化合物,经化学试验和光谱鉴定它们的结构为 β -(3',4'-dihydroxyphenyl)ethyl-O- α -L-rhamnopyranosyl (1 $\rightarrow$ 3)- β -D-glucopyranoside (I), acteoside isomer (II), plantainoside C(III)。

关键词 黑参 酚甙 苯丙素甙

黑参 *Pedicularis decora* France. 为玄参科马先蒿属植物,药用根茎,又名太白参、太白洋参。有“补虚、健脾胃、消炎止痛、滋阴补肾、补中益气之功效,治疗身体虚弱、肾虚骨蒸、潮热关节疼痛,不思饮食”等疾病^[2]。分布于陕西、甘肃、四川和湖北等省,资源丰富。本文报道 3 个酚甙的分离和结构鉴定。

3 个化合物均与三氯化铁试剂和 Molish

试剂呈阳性反应,示为酚甙类化合物。根据 MS, ^1H 和 $^{13}\text{CNMR}$ 以及 DEPT 脉冲试验分析,化合物 I 为酚甙,II、III 为苯丙素甙。

化合物 I 为白色粉末, FAB-MS m/z : 463 $[M+1]^+$, 综合分析 MS、 ^1H 及 $^{13}\text{CNMR}$ 推定分子式 $\text{C}_{20}\text{H}_{30}\text{O}_{12}$ 。 $^1\text{HNMR}$ 示有鼠李糖甲基 δ 1.12(3 H, d, $J=6.3$ Hz), 苯乙基 7 位

* Address: Li Chong, Department of Pharmacy, Lanzhou Medical College, Lanzhou

李 冲 男,副教授,1988 年毕业于华西医科大学药学院,获药物化学专业硕士学位。现在兰州医学院药理学系中草药化学教研室任教。主要从事高原中草药活性成分的研究。完成的研究工作有“藏药独一味化学成分研究”、“锁阳化学成分研究”、“藏药柳茶化学成分研究”、“互叶醉鱼草化学成分研究”、“蒙古糙苏化学成分研究”、“尖叶白蜡树化学成分研究”等。近年来在国内外期刊发表论文 15 篇。

** 甘肃中医学院附属医院药剂科